Abstract Receptors coupled to G proteins have many effects on the heart. Enhanced signaling by Gα s and Gα q leads to cardiac injury and heart failure, while Gα i2 signaling in cardiac myocytes can protect against ischemic injury and β-adrenergic-induced heart failure. We asked whether enhanced Gα i2 signaling in mice could protect against heart failure using a point mutation in Gα i2 (G184S), which prevents negative regulation by regulators of G protein signaling. Contrary to our expectation, it worsened effects of a genetic dilated cardiomyopathy (DCM) and catecholamineinduced cardiac injury. Gα i2 G184S/+
Introduction
The primary pharmacologic therapies that prolong life in congestive heart failure target beta adrenergic (βAR) and angiotensin (AT1) receptor signaling (Dzau 1992; Lechat et al. 1998; MacLellan 2000) . The sympathetic and renin-angiotensin systems activate Gs-and Gq-type G proteins linked to cAMP and Ca ++ signaling. There is abundant clinical and animal model data for the role of βAR and AT1R signaling and Gs and Gq to cause cardiac hypertrophy and heart failure (Schnabel and Bohm 1996) .
In contrast to the deleterious effects of Gs and Gq signaling, there is significant literature on protection by Gi family G proteins, predominantly Gα i2 . Activation of many Gi-coupled receptors (e.g., adenosine, sphingosine-1-phosphate, estrogen, and opioid) can reduce ischemiareperfusion injury. Loss of Gα i2 function also worsens ischemic insults (DeGeorge et al. 2008) , myocyte apoptosis (Chesley et al. 2000; DeGeorge et al. 2008) , and heart failure [Gα i2 knockout mice die prematurely in a model of βAR-induced heart failure (Foerster et al. 2003) ]. These observations have prompted efforts to enhance signaling through Gα i -family G proteins as a means to protect the heart.
Regulator of G protein signaling (RGS) proteins inhibit Gi and Gq protein signaling by increasing their GTPase activity (Hollinger and Hepler 2002) . Blocking RGS action (Zhong and Neubig 2001; McEwen et al. 2002) could enhance protective effects of Gα i2 in the heart. As a test of this idea, we used a point mutation (G184S) in Gα i2 that blocks the binding of RGS proteins, prevents the RGS-mediated suppression of Gα i2 signaling (Lan et al. 2000; Fu et al. 2004) , and enhances Gα i2 signaling in vitro and in vivo (Huang et al. 2006) . We recently showed that Gα i2 G184S mutant mice have reduced myocardial injury in a Langendorff ischemiareperfusion model (Waterson et al. 2011) .
While Gα i2 signaling in myocytes can protect the heart from injury and failure, increased Gα i signaling also, produces negative inotropic effects, functions in inflammatory mechanisms (Fan et al. 2005; Pero et al. 2007; Zarbock et al. 2007) , and may increase fibroblast proliferation and fibrosis ). Consequently, enhancing Gα i signaling as a means to cardioprotection may need to be selective to achieve the desired effect.
Here, we assess, in two distinct models of cardiac injury and heart failure, the effect of increased Gα i2 signaling in mice with an RGS-insensitive Gα i2 subunit. A mouse model of dilated cardiomyopathy (Tg9-DCM), like human heart failure, shows improved survival with angiotensin-converting enzyme inhibition and β 1 AR blockade (Buerger et al. 2006 ) and worsens with abnormal glucose homeostasis (Hruz et al. 2008; Vyas et al. 2011) . Second, isoproterenol injections are used to induce injury and subsequent heart failure (Ozaki et al. 2002) . In both models, loss of RGS action at Gα i2 led to worsened outcomes. In the DCM model, active mutant Gα i2 produced early deaths and increased hypertrophy, and in the Iso-induced injury model, markedly increased fibrosis was seen. Furthermore, cardiac fibroblasts from the Gα i2 G184S/ G184S mutant mice show a pertussis toxin sensitive increase in ERK activation and proliferation in vitro and enhanced collagen gene expression in vivo. Consequently, any manipulations to enhance Gα i2 signaling in the heart should be ) were compared by log-rank (Mantel-Cox) test. ***p<0.001 compared to respective TG9-control. † p<0.05; † † † p<0.001 compared to respective Gα i2 +/+ control. n=9-13. Arrows indicate the time at which tissues were collected in subsequent studies Values are mean±standard error of the mean, n represents animals in each group (9-13). Differences were determined by Mantel-Cox log rank test from the survival curve analysis ND none died up to 95 days *p<0.05, **p<0.001, indicate a significant effect on survival as compared to respective Gα i2 +/+ control selective for myocytes as Gα i2 signaling in other tissues, such as fibroblasts may be detrimental.
Methods
Animals Animal care was supervised by the University of Michigan Unit for Lab Animal Medicine and all animal study protocols were approved by the University Committee on Use and Care of Animals. Animals were maintained under a 12:12-h light-dark cycle with ad libitum access to standard chow and water. Mice with a genomic knock-in of the Gα i2 G184S RGS-insensitivity allele were described previously (Huang et al. 2006) . All studies utilized mice crossed at least five times onto the appropriate genetic background (C57BL/6J or FVB/NJ). The transgenic DCM model, which results from cardiacspecific over-expression of cre-recombinase, was previously described and the transgene is referred to as TG9 + (Buerger et al. 2006 G184S/G184S mice and littermate controls (WT) mice were on the C57Bl/6J background.
Chronic drug treatment in the DCM model Losartan (0.6 g/L) was added to drinking water at 3 weeks of age in TG9 + Gα i2 +/+ vs TG9 + Gα i2 G184S/+ mice. Doses were chosen from a previous report showing protective effects in a vascular model (Habashi et al. 2006) . Survival was assessed up to 95 days for various genotypes and treatments.
Catecholamine-induced cardiac injury Male, Gα i2 G184S/ G184S and WT mice (14-16 weeks old) were treated with Iso (30 mg/kg) or saline via intraperitoneal injection daily for 7 days (Ozaki et al. 2002) .
Cardiac tissue analysis Animals were sacrificed at 10 weeks of age (DCM study) or 24 h after the last Iso or saline injection. Hearts were removed, washed with cold phosphate-buffered saline (PBS), and fixed for histology or frozen in liquid nitrogen for biochemical studies.
Fibrosis and cell size Samples for histology were fixed in 10% formalin for 24 h, paraffin embedded, sectioned, stained with Masson's trichrome, imaged using light microscopy, and photographed (Zeiss Axioplan, Carl Zeiss IMT Corporation, Maple Grove, MN, USA). The percentage with collagen (blue) and without (red) was quantified using Adobe Photoshop (Dahab et al. 2004 ). For myocyte cross-sectional area, 10-20 randomly selected myoctyes per image were measured. Cells were outlined manually (total n =251-333 cells per condition) using the polygon selection tool ImageJ (http://rsb.info. nih.gov/nih-image). Due to the non-normal distribution of cell sizes, statistical analysis was done on the logarithm of cell area values.
mRNA analysis by qPCR RNA isolated from frozen myocardial tissue using RNA STAT-60 reagent (Iso-Tex Diagnostics, Friendswood, TX, USA) was treated with DNase for 15 min at room temperature (Qiagen, Valencia, CA, USA) then quantitative PCR (qPCR) performed after first-strand complementary DNA (cDNA) synthesis (TaqMan Kit, Applied Biosystems, Branchburg, NJ, USA). cDNA was then subjected to qPCR with SYBR green master mix (Stratagene, La Jolla, CA, USA) and 100 pM each of sense and antisense primer. Primers for genes relevant to cardiac hypertrophy (ANP, BNP, SMA, and Col III) and β-actin (an internal control) were described previously (Schoenfeld et al. 1998) . PCR conditions were denaturation at 94°C and 10 min, then 40 cycles of denaturation at 94°C and 30 s, annealing at 60°C and 60 s, then extension at 72°C for 10 min. No-template controls and no-RT controls were run during each experiment to detect RNA and/or DNA contamination. Results are expressed as relative gene expression normalized against β-actin.
Adult cardiac fibroblast culture Cardiac fibroblasts were isolated from 20-to 26-week-old female mice as described by O'Connell et al. (2007) with minor modifications. Briefly, after quick removal, hearts were washed in icecold PBS, then retrogradely perfused through the aorta for 5 min with calcium-free perfusion buffer (NaCl, 120.4 mM; KCl, 5 mM; MgSO 4 ⋅H 2 O, 1.2 mM; Na 2 HPO 4 , 0.6 mM; KH 2 PO 4 , 0.6 mM; Na-HEPES, 10 mM; NaHCO 3 , 4.6 mM; taurine, 30 mM; glucose, 10 mM; and butanedione monoxime, 10 mM, pH 7.4). Hearts were then perfused for 10 min with the same buffer containing 0.5 mg/ml collagenase II (Worthington Biochemicals, Lakewood, NJ, USA, lot no. 46M9065). Hearts were removed from the apparatus and atria were discarded. Ventricles were suspended in perfusion buffer containing 10% serum and 1.25 μmol/L calcium to stop the digestion. Cells were separated from the tissue by gentle pipetting of the digested heart using sterile plastic transfer pipettes. Samples were allowed to settle under gravity for 15 min to remove debris and myocytes. The remaining suspended fibroblasts were centrifuged at 300×g for 10 min and resuspended in Dulbecco's modified Eagle's medium supplemented with 1% penicillin/streptomycin, insulin/transferrin/selenium (ITS from Sigma), and 10% fetal bovine serum (full medium). Cells isolated by this method all stain positively for α-SMA (data not shown).
Fibroblast proliferation Cardiac fibroblasts (passages 3-5) were plated in 24-well dishes (10 4 /well) and allowed to grow in 10% "fetal bovine serum (FBS)-containing medium for the specified time in the presence or absence of pertussis toxin (PTX) (100 ng/ml). At the end of the growth period (1-4 days), medium was aspirated, cells were rinsed with Ca 2+ /Mg 2+ free PBS, and 150 μL of 0.05% trypsin was added to each well. Cells were incubated with trypsin at 37°C for 5 min and then shaken on a plate p<0.001 compared to WT Gα i2 control. n=9-13 in each group. b Change in survival days after losartan treatment. Values are mean±standard error of the mean, n=9-13. ***p<0.001 for drug treatment compared to non-drug control. † p<0.05 compared to respective Gα i2 +/+ control. Differences were determined by one-way ANOVA with Bonferroni post-test shaker at room temperature for 5 min. Then, 50 μL of FBS (100%) was added to stop trypsin action, and 200 μL of 10% formalin was added to fix cells. Cells were collected in microcentrifuge tubes, and 200 μL of this cell suspension was used for cell counting using a flow cytometer (Accuri Cytometers, Inc. Ann Arbor, MI, USA). To study the role of ERK, the mitogen-activated protein/extracellular signalregulated kinase kinase (MEK) inhibitor PD 098059 (30 μM, Cayman Chemical, Ann Arbor, MI, USA) was added to the medium on day 1, and cells were counted on day 3.
ERK phosphorylation measurements Western blotting was performed to assess ERK activation using a phospho-p44/ 42 Erk1/2 Thr202/Tyr204 antibody (no. 9101, Cell Signaling Technology, Inc., Danvers, MA, USA) and a total ERK antibody (no. 9102, Cell Signaling Technology, Inc., Danvers, MA, USA). Cells were seeded at an initial density of 2×10 5 cells/well in 12-well plates and grown in serumcontaining medium for 24 h in the absence or presence of PTX. Cells were washed with cold PBS and lysed with RIPA buffer (Tris, 25 mM; NaCl, 150 mM; NP-40, 1%; sodium deoxycholate, 1%; sodium dodecyl sulfate, 0.1%). The cell lysates (20 μg) were then subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis, immunostained, then visualized using enhanced chemiluminescence (Thermo Scientific, Rockford, IL, USA). The band intensities (p42+p44) were quantified densitometrically, and ERK phosphorylation was expressed as the intensity of the pERK bands normalized to the intensity of the total ERK bands. mice. Mice were injected with saline or isoproterenol (30 mg/kg) daily for 7 days then tissues collected, weighed, and processed for microscopy as described in "Methods." a HW/BW after saline or Iso treatment in WT and RGS-insensitive Gα i2 G184S/G184S mice. b Images of transverse myocardial sections. c Myocyte cross sectional area measured using NIH-Image as described in "Methods." Values are mean±SEM, n=6-8 for HW/BW and >250 for myocyte size in each group. *p<0.05 or ***p<0.001 for Iso-vs saline-treated animals or † † † p<0.001 for WT vs Gα i2 G184S/G184S by ANOVA analysis of variance (ANOVA) with Bonferroni post-test was used to compare multiple data sets. Survival curves were compared by log-rank (Mantel-Cox) test. All statistical calculations were done using GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA, USA), and p< 0.05 was considered significant.
Statistical analyses

Results
Effect of Gα i2 G184S/+ mutation on survival in DCM mice
The TG9 DCM model leads to the development of congestive heart failure and death (Buerger et al. 2006) . As seen previously, the maximum life span for TG9 + Gα i2 +/+ males was 13.5 weeks (95 days, Fig. 1a) , and for females, it was about 12 weeks (85 days, Fig. 1b ). There were no deaths in non-TG9 mice during the 95-day duration of the study, regardless of their Gα i2 genotype. Combining the RGS-insensitive Gα i2 mutation (Huang et al. 2006 ) with the TG9 + mutation significantly worsened survival. TG9
+ Gα i2 G184S/+ male mice survived for maximum of 88 days, and females survived for only 79 days ( Fig. 1a and Table 1, p<0.05 for male and Fig. 1b , p< 0.001 for female).
Effect of the Gα i2
G184S/+ mutation on cardiac hypertrophy in TG9 + mice
At 10 weeks of age (i.e., prior to any deaths), male DCM mice with WT Gα i2 showed a modest increase in HW/BW, which was markedly greater in the double-mutant TG9+ Gα i2 G184S/+ mice (Fig. 2a, p<0 .001, two-way ANOVA vs Gα i2 G184S/+ controls and p<0.01 vs DCM Gα i2 +/+ mice). Consistent with the earlier onset of heart failure, 10-week-old TG9 + Gα i2 G184S/+ male mice also showed a significant increase in lung weight to body weight ratio (LW/BW, Fig. 2b ) compared to both TG9 − controls (p<0.01) and TG9 + mice with WT Gα i2 (p<0.01). Female mice of both Gα i2 genotypes showed significant hypertrophy at 10 weeks, 20.2±4.1% and 40.1±3.2% increase in HW/BW, respectively, for DCM Gα i2 and Gα i2 G184S/+ compared to their non-DCM controls (Fig. 2c, p<0.001) . The difference between DCM Gα i2 G184S/+ and DCM Gα i2 +/+ was not statistically significant most likely due to the more advanced progression of heart failure in females at 10 weeks. TG9 + Gα i2 +/+ and TG9 + Gα i2 G184S/+ female mice both had significant increases in LW/BW (17.0± 7.9% vs 32.2±4.5%, p<0.05 and p<0.001, respectively).
Effect of Gα i2
G184S/+ mutation on marker gene expression and fibrosis
Heterozygous Gα i2
G184S/+ mutant mice had normal expression of all four of the marker genes studied (ANP, BNP, SMA, and Col III, Figs. ESM1 and ESM2), while DCM mice had marked increases. As seen for HW/BW, male DCM mice carrying the Gα i2 G184S/+ mutation showed a greater increase in ANP and BNP expression at 10 weeks vs DCM alone (ANP, p<0.001; BNP, p< 0.01). In contrast, DCM females showed major increases in natriuretic peptide gene expression, but there was no further effect of the Gα i2 G184S/+ mutation (Fig. ESM2 ).
The effect of the Gα i2 G184S/+ mutation appears to have been overshadowed by the earlier onset of heart failure in the females.
Both male and female DCM mice exhibited a modest increase in fibrosis compared to non-DCM mice, but there was no augmentation when they were carrying the Gα i2 G184S/+ mutation vs WT Gα i2 (data not shown). This result was in agreement with the levels of expression seen for Col III (Figs. ESM1D and ESM2D ).
Effect of losartan treatment
To assess signaling pathways that might be involved in worsened cardiac failure with the Gα i2 G184S/+ mutation, we tested pharmacological blockade of angiotensin II signaling. Female mice, chosen due to the greater effect of the Gα i2 G184S/+ mutation, were given drinking water containing losartan starting at 3 weeks of age. Losartan treatment significantly improved survival. The difference between the control and losartan treatment groups was highly significant for both genotypes (Fig. 3a, p<0. (Fig. 3b, p<0.05 ).
Catecholamine injury model: effect of Gα i2 G184S mutation
Seven days of Iso treatment resulted in one death among the nine WT mice (on day 4) while three of the nine RGSinsensitive Gα i2 G184S/G184S mice (or G184S/G184S) mice died on the second day of Iso treatment. As reported previously (Huang et al. 2006) , there was a modestly greater HW/BW in homozygous Gα i2 G184S/G184S mice than in WT mice (p<0.01, unpaired, t test). Iso treatment increased HW/BW in both WT and mutant mice (Fig. 4a ). There were significant effects of both treatment (p<0.001) and genotype (p < 0.05) by two-way ANOVA and a Bonferroni post-test showed significant Iso effects (Fig. 5a, p<0 .05) for both WT and Gα i2 G184S/G184S mice. Since heart weight is determined by both myocyte and non-myocyte elements, we also assessed myocyte size (Fig. 4b, c) , which was 24% greater in the hearts from saline-treated mutant mice (262 μm 2 ) compared to those from WT mice (211 μm 2 ), consistent with the 30% greater HW/BW. Iso treatment increased myocyte size in WT mice (293 vs 211 μm 2 ), while for Gα i2 G184S/G184S , cell size was unchanged (261 vs 262 μm 2 ) despite an increase in HW/ BW of 32%. The lack of effect on myocyte size for mutants in the face of increased HW/BW suggests a role of nonmyocyte elements in the Iso-induced cardiac hypertrophy in mutant mice (see below). Increased fibrosis in Gα i2 G184S/G184S mutant hearts after Iso. a Cardiac sections were stained with Masson's trichrome after saline or isoproterenol treatment of wild-type (WT) or Gα i2 G184S/G184S mice. b Digital quantification of the tissue fibrosis was done as described in "Methods." Values are mean±SEM, n=6 in each group. **p<0.01 Iso-vs saline-treated animals. † † † p<0.001 Gα i2 G184S/G184S vs WT animals Effect of Gα i2 G184S mutation on marker gene expression and fibrosis Mutant mice had significantly higher basal expression of BNP (Fig. 5, p<0.05) . ANP in saline-treated Gα i2 G184S/G184S mice also was significantly greater (750±290% of WT values, p< 0.05, by non-paired t test). Iso treatment significantly increased the expression of ANP and SMA in both WT and Gα i2 mutant mice (Fig. 5, p<0.05) ; however, the magnitude was not different between the WT and mutant mice.
Saline
Mutants, however, showed a markedly increased expression of Col III messenger RNA (mRNA; 725±172%, p<0.01) after Iso with no effect in WT mice. The difference between WT and Gα i2 G184S/G184S mice after Iso treatment was also highly significant (p<0.001, Fig. 5 ).
Effect of Gα i2
G184S mutation on fibrosis
To understand the functional relevance of this increase in Col III mRNA expression, we analyzed cardiac fibrosis by trichrome staining (Dahab et al. 2004) . Consistent with the gene expression results, there was a marked increase in fibrosis in mutant mice after Iso treatment (p<0.01), and this level of fibrosis was much greater than that seen in WT hearts after Iso treatment (p<0.001, Fig. 6a, b) . The effect of Iso treatment on fibrosis in WT mice (264±58% of saline), was not statistically significant.
Effect of Gα i2 G184S mutation on cardiac fibroblast proliferation
We examined cardiac fibroblasts and found a marked difference in their growth properties under normal growth conditions (i.e., 10% FBS). Cardiac fibroblast were isolated from three WT and three Gα i2 G184S/G184S mice and mutant cells grew significantly faster than WT (Fig. 7a, b) ; 104±45% more at 3 days in culture (p<0.05). There was no difference between WT and mutant fibroblast proliferation in low serum medium (Table ESM1) . Fibroblast numbers were significantly decreased by PTX treatment for both mutant (p<0.001) and WT (p<0.05). After PTX, the difference in the fibroblast numbers between WT and mutant was not significant, so ongoing signaling through PTX-sensitive mechanisms (presumably via Gα i2 coupled receptors) contributes to increased proliferation/ survival of the Gα i2 G184S/G184S cardiac fibroblasts.
Effect of Gα i2 G184S mutation on cardiac fibroblast ERK signaling Mutant cardiac fibroblasts grown in serum-containing medium had increased phospho-ERK levels (207±34% of WT, Fig. 8b , p<0.05). This increased ERK phosphorylation was abolished by PTX treatment (p<0.05) and was absent in mutant cardiac fibroblast grown in serum free medium (Fig. 8c) . To determine whether this might contribute to the enhanced proliferation/survival of Gα i2 G184S/G184S mutant fibroblasts, we evaluated treatment with the MEK inhibitor, PD 98059, which significantly decreased the number of mutant fibroblasts (Fig. 8d, p<0 .05), while it had no effect on WT fibroblasts.
Discussion
The unclear significance of Gα i2 signaling in myocardial injury complicates efforts to modulate its function as a G184S/G184S vs WT cells. *p<0.05 or ***p<0.001 for the effect of PTX therapeutic strategy. Early reports showing increased Gα i2 expression in heart failure patients (Feldman et al. 1988) did not differentiate between cause and effect regarding complications of heart failure. Recent studies on protective roles of Gα i2 signaling (Chesley et al. 2000; Foerster et al. 2003; DeGeorge et al. 2008 ) studied myocytes or used in vivo genetic manipulations specific to myocytes perhaps missing a role for other cell types. Here, we used a Gα i2 G184S RGS-insensitive mouse model of enhanced Gα i2 signaling cardiac pathophysiology. We recently showed that these mice are protected from myocardial ischemia/reperfusion injury (Waterson et al. 2011) . However, in heart failure models examined here, detrimental effects were seen. Gα i2 G184S mutant mice show early mortality in the DCM model, which is partially ameliorated by angiotensin receptor blockade. In addition, they have markedly increased fibrosis after Iso-induced injury in vivo and increased cardiac fibroblast ERK activity and cell proliferation. These results further emphasize the growing realization that signaling in fibroblasts, as well as that in myocytes, may be key to understanding cardiac pathophysiology (Baudino et al. 2006) .
The best evidence for a protective role of Gα i in heart failure comes from studies of the β2-AR. Overexpression of the β1-AR causes severe heart failure (Engelhardt et al. 1999 ) but similar expression of the β2-AR does not (Foerster et al. 2003) . This has been attributed to a Gi-dependent anti-apoptotic effect in cardiac myocytes (Chesley et al. 2000; DeGeorge et al. 2008) . Knockout of Gα i2 (Foerster et al. 2003; DeGeorge et al. 2008) or pertussis toxin treatment of myocytes in vitro (Chesley et al. 2000) reverses the apparent protection afforded by Gi signaling. Consequently, the adverse outcomes seen here with RGSi mutation-induced enhancement of Gα i2 signaling were surprising.
Fibroblasts are key cells in cardiac remodeling, but we are not able to discriminate with this study whether they 
G184S/G184S
Cells/well x 10 -3 D Fig. 8 Increased ERK activity controls proliferation of RGSinsensitive Gα i2 cardiac fibroblasts. Cardiac fibroblasts from wildtype (WT) or Gα i2 G184S/G184S mice were grown for 24 h in complete medium without (PTX-) or with (PTX+) PTX. a Representative blot for phospho-ERK and total ERK assessed as in "Methods." b Densitometric analysis of phospho-ERK/total ERK normalized to the value of the PTX-WT cells. c After growing for 24 h in complete medium, cardiac fibroblasts were starved with serum-free medium overnight, and samples were analyzed for phospho-ERK and total ERK expression. d The effect of the MEK inhibitor PD 98059 on fibroblast number was assessed after 3 days in culture with DMSO or 30 μM PD 98059. Values are mean±SEM for fibroblasts from three different animals with each assay done in duplicate. † p<0.05 Gα i2 G184S/G184S vs WT cells. *p<0.05 vehicle-vs PTX-or PD 98059-treated cells initiatiated the pathophysiological response or if they were simply responding to the myocyte dysfunction and death occasioned by cardiac injury. Future studies will be needed to determine that. In the context of the Gα i2 G184S mice, catecholamine-induced cardiac injury did lead to more fibrosis, while in the DCM model the mutation seems to primarily facilitate hypertrophy. Although there was no a direct link between the Iso-induced fibrosis and the decline in DCM survival, end points for both models show a common detrimental role of enhanced Gα i2 signaling.
The fibrosis after high-dose Iso treatment is consistent with known Gi signaling in cardiac fibroblasts by thrombin (Sabri et al. 2002) and lysophosphatidic acid (LPA) (Epperson et al. 2009 ). RGS-insensitive Gα i2 MEFs show increased LPA-stimulated ERK and Akt phosphorylation (Huang et al. 2006) , so LPA may be the serum factor causing the enhanced our Gi-and ERK-pathway-dependent proliferation. The Gi-linked LPA 3 receptor induces proliferation and collagen synthesis in cardiac fibroblasts (Chen et al. 2006) , and LPA levels in serum are markedly increased after myocardial infarction (Chen et al. 2003) .
The modest increases in HW/BW in the Gα i2
mice [Huang et al. (2006) and Fig. 4a ] could have been either physiologic hypertrophy, protective against heart failure, or pathologic hypertrophy that would worsen heart failure. Our present data now point to pathological hypertrophy. Earlier death in the DCM transgenic heart failure model provides one of the hallmarks of pathological hypertrophy (i.e., exacerbation of other hypertrophic insults). Furthermore, the increased expression of "hypertrophy genes" such as BNP and ANP is characteristic of pathologic hypertrophy. The Gα i2 G184S/G184S homozygotes showed increases in natriuretic peptide expression at baseline, while both Iso and DCM insults led to substantially higher hypertrophy gene expression in the mutants.
Angiotensin AT1 receptors may contribute in the DCM model. Losartan produces improved survival of DCM mice, and this was significantly greater for mice with the Gα i2 G184S/+ mutant (Fig. 3b, c) . In addition to G q signaling, AT1 receptors can activate Raf-1 and ERK in liver epithelial cells (Tsygankova et al. 1998 ) and increase proliferation and ERK activation with cardiac fibroblasts (Zou et al. 1998 ) via PTX-sensitive signals. Enhanced AT1 receptor activation of Gα i2 , perhaps in fibroblasts, may contribute to the worsened heart failure in Gα i2 G184S mice. Our results raise a number of questions for future consideration. First, which RGS proteins control Gα i2 signaling relevant to the worsened injury, and do they differ from those in myocytes that suppress Gα i2 -mediated protective effects seen in the ischemia-reperfusion model (Waterson et al. 2011) ? If so, one could target the latter pharmacologically (Neubig and Siderovski 2002; Riddle et al. 2005; Blazer et al. 2011 ) to improve outcomes in myocardial infarction with less risk of complications from subsequent heart failure. Second, which receptors signal through Gα i2 to induce the worsened heart failure and fibrosis? Identification of these receptors could reveal potential targets of therapeutic intervention. While angiotensin blockade improves survival in the DCM model, we cannot say that this is a direct effect of AT1R on Gα i2 as it could be a downstream action such as from released chemokines, S1P, etc., which act through Gicoupled pathways. Studies to assess these questions are ongoing.
In summary, we asked whether the whole-body knock-in of the RGS-insensitive Gα i2 G184S mutation could protect against cardiac injury and heart failure. We show, however, that in two animal models, RGS proteins through their action on Gα i2 appear to play a protective role perhaps in part by reducing ERK activity and proliferation of cardiac fibroblasts.
